Schizophrenia: susceptibility genes and oligodendroglial and myelin related abnormalities

Panos Roussos1,2,3 * and Vahram Haroutunian1,2,4

1 Mental Illness Research, Education, and Clinical Center (VISN 3), James J. Peters VA Medical Center, Bronx, NY, USA
2 Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, NY, USA
3 Department of Genetics and Genomic Science and Institute for Multiscale Biology, Icahn School of Medicine at Mount Sinai, New York, NY, USA
4 Department of Neuroscience, Icahn School of Medicine at Mount Sinai, New York, NY, USA

Edited by: Martin Stangel, Hannover Medical School, Germany
Reviewed by: Jan Stenmark, University of Oslo, Norway
Karolina A. Aberg, Virginia Commonwealth University, USA
Corinna Klein, AbbVie Deutschland GmbH & Co KG, Germany
*Correspondence: Panos Roussos, Department of Psychiatry and Department of Genetics and Genomic Science and Institute for Multiscale Biology, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, New York, NY 10029, USA.
email: panagiotis.roussos@mssm.edu

INTRODUCTION

The core symptoms of schizophrenia include the presence of delusions and hallucinations (positive symptoms), apathy, and social withdrawal (negative symptoms), as well as, stable impairments in specific domains of cognitive function. Despite our best effort, we still lack a basic understanding of the etiopathogenesis of schizophrenia and therefore tools for curative treatment or prevention do not exist (Insel, 2010). Given the high prevalence of schizophrenia (1% or more) the need for greater understanding is urgent.

Most efforts in understanding the cellular basis of schizophrenia have followed a “neuron-centric” approach, focusing exclusively on the role(s) of neurons. This has led to findings of alterations in neuronal function, such as neurotransmission and synapse cytoarchitecture, often overlooking the fact that neuronal function and neurotransmission is intrinsically dependent on interactions between neurons and glia. Increasing recognition of the importance of neuro-glial elements as basic functional units (Allen and Barres, 2009) that participate in CNS function and dysfunction combined with multiple lines of evidence showing abnormalities in oligodendrocytes and myelination have implicated oligodendrocytes as highly relevant to schizophrenia. While the approach of grouping neurons and glia into neuro-glial functional units introduces significant complexity into the analysis of the neurobiology of schizophrenia, it encourages an integrative approach that favors the examination of the interplay between neurons and the more abundant glial cell types of the CNS.

Given that the genetic risk for schizophrenia is highly polygenic and the effect sizes, even for rare or de novo events, are modest at best, it has been suggested that multiple biological pathways are likely to be involved in the etiopathogenesis of the disease. Most efforts in understanding the cellular basis of schizophrenia have followed a “neuron-centric” approach, focusing on alterations in neurotransmitter systems and synapse cytoarchitecture. However, multiple lines of evidence coming from genetics and systems biology approaches suggest that apart from neurons, oligodendrocytes and potentially other glia are affected from schizophrenia risk loci. Neurobiological abnormalities linked with genetic association signal could identify abnormalities that are more likely to be primary, versus environmentally induced changes or downstream events. Here, we summarize genetic data that support the involvement of oligodendrocytes in schizophrenia, providing additional evidence for a causal role with the disease. Given the undeniable evidence of both neuronal and glial abnormalities in schizophrenia, we propose a neuro-glial model that invokes abnormalities at the node of Ranvier as a functional unit in the etiopathogenesis of the disease.

Keywords: systems biology, polygenic, node of Ranvier, disconnectivity, GWAS

Here, we first outline genetic evidence derived from candidate gene association studies or genome-wide approaches that support oligodendroglial and myelin related (OMR) abnormalities in schizophrenia as a primary contributor. In an attempt to provide a mechanistic and integrative interpretation of the neuronal and OMR changes in schizophrenia, we introduce a neuro-oligodendroglial model that involves abnormalities at the nodes of Ranvier (NOR) as a functional unit implicated in the etiopathogenesis of the disease.

MYELIN ASSOCIATED ABNORMALITIES IN SCHIZOPHRENIA

Myelination can increase action potential transmission speed and decrease refractory time, which increases the number of action potentials that can be transmitted per unit time. There is accumulating evidence supporting the notion of schizophrenia as a disorder of disconnectivity (Konrad and Winterer, 2008). While disconnectivity can be caused by different mechanisms, such as synaptic malfunction, at its core, it implicates inadequate or failed information transfer among neurons. OMR abnormalities in schizophrenia impair the saltatory conduction and information conduction from one neuron to others.

Growing evidence, accumulated over the last 15 years, provides strong support for OMR abnormalities in schizophrenia. The majority of those data is derived from neuroimaging and human postmortem studies (for review, see Sequeira et al., 2012; Fitzsimmons et al., 2013). Irrespective of the level of care and control, different confounding factors, such as antipsychotic medication, could contribute to the detected OMR neuroimaging.

"fncel-08-00005" — 2014/1/18 — 19:38 — page 1 — #1
gene expression, and proteome abnormalities in schizophrenia. Therefore, incorporating genetic data, as discussed below, can help distinguish whether OMR changes are a primary contributor to disease pathophysiology vs. secondary changes associated with other primary lesions existing in schizophrenia or mere epiphenomena.

GENETIC ASSOCIATION OF OMR CANDIDATE GENES IN SCHIZOPHRENIA

Multiple candidate studies have provided evidence that OMR genes are genetically associated with schizophrenia (Table 1). It is interesting to note, that the products of these same genes have been implicated in numerous direct studies of OMR gene and protein expression in the brains of persons with schizophrenia, as well as, neuroimaging studies, providing a stronger support for causality with the disease (Bartolozzi, 2011; Takahashi et al., 2011). The OMR genes with the strongest support for genetic association with schizophrenia are described below.

Neuregulin 1 (NRG1) - ERBB4 signaling

NRG1 risk genotypes or haplotypes have been associated with schizophrenia (Stefanis et al., 2002). Genetic evidence also supports ERBB4 – the NRG1 receptor – as a candidate susceptibility gene and suggests positive epistatic interactions between NRG1 and ERBB4 in schizophrenia (Norton et al., 2006). The potential pathophysiologic role of NRG1 is further supported by its diverse neurobiological functions, including neuro-glial trophic effects and myelination (Harrison and Law, 2006). Nevertheless, given the fact that the NRG1 – ERBB4 signaling has multiple effects in nervous system development (including neuronal migration and modulation of neurotransmission), this pathway may play a role in schizophrenia pathogenesis through other mechanisms aside from OMR effects. A direct way to assess the pathophysiologic effects of genetic variants would be to examine human subjects with risk variants for symptoms of schizophrenia. Along these lines, many groups have reported association of the NRG1 – ERBB4 risk variants with neurocognitive (Stefanis et al., 2007), electrophysiological (Roussos et al., 2011) and neuroimaging schizophrenia-related outcome variables, including altered fronto-temporal brain function (Hall et al., 2006) and white matter density and integrity (McIntosh et al., 2008; Konrad et al., 2009). Finally, several groups have assessed gene expression and proteins of NRG1 and ERBB4 in postmortem brains and have reported differences between schizophrenia and healthy control groups (Hashimoto et al., 2004; Law et al., 2006).

Disrupted-in-schizophrenia 1

Disrupted-in-schizophrenia 1 (DISC1) is a strong candidate gene for schizophrenia and was initially identified in a large Scottish pedigree (Millar et al., 2000) followed by additional genetic evidence for association with sporadic cases of schizophrenia (Chubb et al., 2009). Recent studies in zebrafish (Drerup et al., 2009) and transgenic mice (Katsel et al., 2011) with forebrain restricted transcripts that in vitro experiments demonstrated that cultured neurons expressing the schizophrenia-associated RTN4R variants failed to respond to the growth inhibiting activity of myelin, and functioned as a dominant negative to disrupt endogenous RTN4R (Budel et al., 2008).

Other genes

Oligodendrocyte lineage transcription factor 2 (OLIG2) encodes a transcription factor central to oligodendrocyte development (Ross et al., 2003). Genetic association analysis showed that OLIG2 is associated with schizophrenia and demonstrated an epistatic effect with 2',3'-cyclic nucleotide 3'-phosphodiesterase (CNP) and ERBB4 (Georgeva et al., 2006). Furthermore, OLIG2 expression significantly correlated in cerebral cortex with CNP and ERBB4, suggesting that variation in OLIG2 confers susceptibility to schizophrenia as part of a network of genes implicated in oligodendrocyte function. Similarly, a genetic association of the CNP gene was found for schizophrenia (Prince et al., 2006). The CNP risk polymorphism was associated with lower gene expression which is consistent with CNP gene expression downregulation in schizophrenia.

GENETIC ASSOCIATION OF OMR GENES IN SCHIZOPHRENIA DERIVED FROM GENOME-WIDE APPROACHES

Significant progress has been made over the last decade through large genome-wide association studies (GWAS). The GWAS design has provided evidence in an agnostic manner that specific common DNA genetic variants among people influence their genetic susceptibility to multiple different complex disorders, including schizophrenia (Ripke et al., 2013). Furthermore, we have learned that the genetic risk for schizophrenia is highly polygenic (Ripke et al., 2013), where the phenotype is influenced by multiple genetic variants, each one with small effect sizes. Here, we present results for association of each OMR gene with schizophrenia according to the largest published schizophrenia GWAS data set (PGC-SWE; https://pgc.unc.edu/; Ripke et al., 2013). No OMR genetic association reached genome-wide significance (Table 1); however, a handful of OMR genes (ANK3, ERBB4, and NRG1) show suggestive association (P < 5 × 10^{-8}). Future GWAS with increased sample sizes will determine whether OMR genetic variants are true associations at reduced thresholds, but without the needed power to reach genome-wide significance.

Systems biology approaches allow the integration of multiscale datasets gained from genetic imaging and gene and protein
Table 1 | OMR genes implicated in schizophrenia.

| Gene | Genetic evidence | PGC-SWE P | Rank | Altered gene expression | Altered proteome |
|------|------------------|-----------|------|-------------------------|------------------|
| ANK3 | Athanasiu et al. (2010), Roussos et al. (2012a), Yuen et al. (2012b) | 1.31E−05 | 2 | Roussos et al. (2012a) | Cruz et al. (2009), Roussos et al. (2012a) |
| CLDN1 | | 9.04E−05 | 5 | Tsai et al. (2003), Katsel et al. (2005), Dracheva et al. (2006), Roussos et al. (2012a,b) | |
| CNP | Peric et al. (2006), Voinikos et al. (2008) | 3.94E−03 | 19 | Hamed et al. (2001), Katsel et al. (2005), Dracheva et al. (2006), McCullumsmith et al. (2007), Barley et al. (2009), Roussos et al. (2012b) | Prabakaran et al. (2004), Dracheva et al. (2006) |
| CNTNAP2 | Freedman et al. (2008), Wang et al. (2010), Ji et al. (2013) | 3.96E−04 | 10 | Roussos et al. (2012a) | |
| DISC1 | Millar et al. (2005), Saetre et al. (2008), Song et al. (2008), Rakogi et al. (2009), Ayalew et al. (2012), Debono et al. (2012) | 1.04E−03 | 13 | Hukata et al. (2009) | Ratta-Agha et al. (2013) |
| ERBB3 | Li et al. (2009) | 9.70E−05 | 6 | Tsai et al. (2003), Katsel et al. (2005), Roussos et al. (2012b) | |
| ERBB4 | Norton et al. (2006), Silberberg et al. (2006), Agim et al. (2013) | 2.80E−06 | 1 | Silberberg et al. (2006), Law et al. (2007) | Cheng et al. (2008) |
| MAG | Wen et al. (2005), Yang et al. (2005) | 1.96E−03 | 16 | Tsai et al. (2003), Katsel et al. (2005), Dracheva et al. (2006), McCullumsmith et al. (2007), Barley et al. (2009), Roussos et al. (2012b) | |
| MAL | Ayalew et al. (2012) | 8.23E−03 | 21 | Hukata et al. (2001), Katsel et al. (2005) | |
| MBP | Ayalew et al. (2012) | 4.23E−04 | 11 | Tsai et al. (2003), Matthews et al. (2012) | Martins-de-Souza et al. (2009a,b) |
| MOBP | Liu et al. (2005) | 6.65E−03 | 20 | Tsai et al. (2003) | |
| MOG | | 1.06E−02 | 23 | Tsai et al. (2003), Katsel et al. (2005), Barley et al. (2009), Roussos et al. (2012b) | Martins-de-Souza et al. (2009a) |
| NFASC | | 2.57E−04 | 8 | Roussos et al. (2012a) | |
| NRCAM | Ayalew et al. (2012) | 1.14E−03 | 14 | Roussos et al. (2012a) | |
| NRG1 | Staffanson et al. (2002), Ayalew et al. (2012), Wiedert et al. (2012), Agim et al. (2013) | 3.24E−05 | 3 | Hashimoto et al. (2004), Law et al. (2006), Tan et al. (2007) | Cheng et al. (2008) |
| OLIG2 | Georgieva et al. (2006) | 2.13E−03 | 17 | Tsai et al. (2003), Katsel et al. (2005) | |
| PLP1 | Om et al. (2005) | NA | NA | Tsai et al. (2003) | |
| PMP22 | Kirov et al. (2009) | 1.38E−03 | 15 | Katsel et al. (2005), Dracheva et al. (2006) | |
| PTHR2 | Buisbaum et al. (2006) | 6.21E−05 | 4 | | |
| QKI | Abern et al. (2000b), Ayalew et al. (2012) | 1.08E−04 | 7 | Katsel et al. (2005), Abern et al. (2006a), McCullumsmith et al. (2007) | |
| RTN4R | Bitul et al. (2008) | 6.75E−04 | 12 | | |
| SOX10 | Manico et al. (2007), Yuan et al. (2012a) | 8.24E−03 | 22 | Tsai et al. (2003), Katsel et al. (2005), Dracheva et al. (2006) | |
| CNTN2 | Ayalew et al. (2012) | 2.57E−04 | 8 | Roussos et al. (2012a,b) | |
| TF | Ou et al. (2009) | 2.25E−03 | 18 | Hukata et al. (2001), Katsel et al. (2005), McCullumsmith et al. (2007), Roussos et al. (2012b) | Prabakaran et al. (2004) |

The largest PGC-SWE (Ripke et al., 2013) in the form of summary statistic p-values was obtained from public access website (https://pgc.unc.edu/). For each gene (±100 kb from 5' and 3' ends of gene), the strongest p-value association is provided in the “PGC-SWE P” column. The “Rank” column indicates the ranking of the illustrated genes based on the strength of association with the schizophrenia GWAS data set.
expression studies. The risk SNPs are unlikely to be randomly distributed, but cluster in molecular subnetworks affecting specific cellular populations and molecular processes (Roussos, 2012; Figure 1A). Recent findings support the notion that polygenic risk for schizophrenia affects OMR gene networks and molecular pathways (Roussos et al., 2012b; Goudriaan et al., 2013). Perturbations in specific subnetworks related to neuronal function, myelination, immune response, and energy production were identified in a multi-regional system-level analysis of the schizophrenia brain transcriptome (Roussos et al., 2012b). The subnetworks related to neuronal function and myelination were enriched for genetically associated variants in schizophrenia, providing independent support for the neuro-oligodendroglial interactions as a potential causal functional unit in schizophrenia. No enrichment for genetic variants and immune response and energy production related subnetworks was found, suggesting that these changes may represent secondary or bystander phenomena or be attributable to environmental influences. Similar results were reported in an independent study, in which the genetic evidence for primary roles of specific glial cell type functions and pathways was examined based on gene set analysis (Goudriaan et al., 2013). In conclusion, recent systems biology approaches support the notion that schizophrenia involves hundreds of genetic loci that in combination with environmental factors converge to perturb a more selective/restrictive set of molecular/cellular networks and integrative functions.

FUNCTIONAL NEURO-GLIAL UNITS AND THE NODES OF RANVIER

The above observations suggest that genetic alterations underlying OMR cell-type functions increase susceptibility to schizophrenia and provide evidence that the “neuron-centric” hypothesis of schizophrenia should be extended to include a role for glia in the etiopathogenesis of the disease. The NOR is one of the best example of the neuroglial cell–cell interactions in the central nervous system. The NORs are myelin-sheath-free segments along myelinated axons, where sodium ion exchange takes place propagating action potentials from the axon initial segment to the axon terminal. NOR and OMR gene and protein expression abnormalities can hamper saltatory conduction by affecting NOR formation, maintenance, and integrity, which in turn leads to failures of saltatory conduction and disconnection of higher-order association areas (Nave, 2010).

Different and specific neuronal and oligodendroglial reciprocal interactions (for review, see Poliaik and Poles, 2003) ensure the high concentration and anchoring of voltage gated Na+ channels (NaV1.6 in adults – SCN8A) to the NOR and the maintenance of adherens junctions between the axolemma and paranodal myelin loops (Figure 1B). The voltage gated Na+ channel cytoplasmic loops are linked to the underlying spectrin-actin cytoskeleton through the anchoring protein Ankyrin G (ANK3). ANK3 plays an important role in the NOR complex by anchoring not only the NaV to the node but also because several cis acting nodal and paranodal adherens junction proteins, such as neurofascin (NFASC), neuronal cell adhesion molecule (NRCAM), contactin 1 and caspr, are also associated with it. Finally, contactin 2 (CNTN2), along with Caspr interact in trans with cell adhesion molecules of oligodendroglial paranodal loops that include an isoform of NFASC (Nf155), and CNTN2 to ensure the integrity of the myelin-axolemma tight junctions, which form a barrier that prevents the diffusion of Nav from the nodal region.

**Figure 1** | Neuro-glial functional unit and the disconnectivity syndrome in schizophrenia. (A) Constellations of multiple genetic and environmental perturbations affect molecular states of gene coexpression and protein–protein interaction networks in the neuro-glial functional unit that in turn increase the risk for schizophrenia. (B) The NOR is the site of intimate neuroglial cell-cell interactions in the nervous system. Abnormalities in the expression of NOR genes and proteins in schizophrenia hamper saltatory conduction by affecting NOR formation, maintenance and integrity and lead to the disconnectivity syndrome.
A recently study demonstrated that several NOR genes and proteins, including ANK3, NFASC, NRCAM, CNTN2, and SCNA10 are affected in schizophrenia (Roussos et al., 2012a). The importance of ANK3 to serious mental illness is further supported by recent GWAS implicating ANK3 in schizophrenia (Athanasia et al., 2010) and bipolar disorder (Sklar et al., 2011). Furthermore, an ANK3 risk polymorphism is associated with decreased ANK3 gene expression, which is consistent with ANK3 gene expression down-regulation in schizophrenia and neurocognitive and neuroimaging abnormalities (Roussos et al., 2012a). Overall, these data highlight that in addition to OMR changes in schizophrenia, abnormalities in how myelin sheaths interact with the axon to form the NOR are also present and identify the NOR as a functional neuro-glial unit where neuronal and OMR genetic perturbations could potentially converge.

CONCLUSION

There are multiple lines of evidence derived from neuroimaging, molecular and genetic data that support a role of OMR genes and molecular pathways in schizophrenia. Recent systems biology and pathway analyses that integrate gene expression and genetic data support the notion that oligodendroglial abnormalities are among the primary deficits in the disorder. Future studies need to integrate the larger GWAS and determine the polygenic effect of OMR changes in schizophrenia. While most efforts in understanding the cellular basis of schizophrenia have followed a “neuron-centric” approach, there is an emerging need to conduct more complex neurobiological studies and examine the neuro-glial unit as a whole. The data to date provide evidence for abnormalities in the NOR as a plausible biological substrate for the disconnectivity syndrome in schizophrenia. Recent evidence suggesting that antipsychotics may influence OMR function beneficially provides clues for improved treatment strategies (Ren et al., 2013). Therefore, a more thorough understanding of the role of OMR and NOR pathology is necessary since it holds the potential for providing new insights into the treatment of this disease.

AUTHOR CONTRIBUTIONS

Panos Roussos and Vahram Haroutunian drafted and revised the manuscript.

ACKNOWLEDGMENTS

We thank Dr. Georgios Voloudakis for figures. We apologize for any errors. We thank Dr. Georgios Voloudakis for figures. We apologize for any errors.
genes in chronic schizophrenia. Proc. Natl. Acad. Sci. U.S.A. 98, 4746–4751. doi: 10.1073/pnas.01171198

Hall, J., Whalley, H. C., Job, D., Lemos, G. K., Munro, M., Miskiw, J., et al. (2006). A neuregulin 1 variant associated with abnormal cortical function and psychotic symptoms. Nat. Neurosci. 9, 1475–1479. doi: 10.1038/nn1709

Hashimoto, R., Straub, R. E., Weickert, C. S., Hyde, T. M., Kleinman, J. E., and Weickert, C. S. (2008). Disturbed structural connectivity in the anterior cingulate cortex indicates the involvement of cytoskeleton, oligodendrocyte, and new potential markers in schizophrenia. J. Neural Transm. 115, 177–173. doi: 10.1007/s00702-007-0169-8

Kirov, G., Grozeva, D., Norton, N., Ivanov, D., Millar, J. K., et al. (2009b). Alterations in oligodendrocyte proteins, calcium homeostasis and mitochondrial dysfunction in schizophrenia. J. Neural Transm. 116, 275–289. doi: 10.1007/s00702-008-0021-5

Li, X., Feng, G., and Hu, J. (2008). Case-control study of association between the functional candidate gene EBBR1 and schizophrenia in Chinese population. World J. Biol. Psychiatry 9, 559–598. doi: 10.1501/wjbp-9-3-559

Liu, X., Qin, W., Hu, G., Yang, Y., Chen, Q., Zhou, J., et al. (2005). A family-based association study of schizophrenia risk and several SNPs associated with schizophrenia in the Chinese population. Schizophr. Res. 73, 275–281. doi: 10.1016/j.schres.2004.07.018

Munro, N., Takeda, N., Saito, J., X. K., Ichihara, B., Araya, N., et al. (2005). Association of SOC10 with schizophrenia in the Japanese population. Psychiatr. Genet. 15, 227–231. doi: 10.1097/01.pgg.0000195103.00442

Nakata, K., Lipka, B. K., Hyde, T. M., Ye, T., Newburg, E. N., Morris, Y., et al. (2009). DSC2 splice variants are upregulated in schizophrenia and associated with risk polymorphisms. Proc. Natl. Acad. Sci. U.S.A. 106, 15875–15878. doi: 10.1073/pnas.0907530106

Nunes, K. A. (2010). Myelination and support of neural integrity by glia. Nature 468, 244–252. doi: 10.1038/nature09364

Norton, N., Mombour, Y., Morris, D. W., Brug J. L., Zanetti, S., Williams, N. M., et al. (2006). Evidence that interaction between neuregulin 1 and its receptor erbB4 increases susceptibility to schizophrenia. Am. J. Med. Genet. B Neuropsychiatr. Genet. 141B, 96–109. doi: 10.1002/ajmg.b.30236

Norweg, G., Kim, D., Seeman, P., and Tallerico, T. (2002). Schizophrenia and Nogo-66 elevated mRNA in cortex, and high prevalence of a homologous CAA insert. Brain Res. Mol. Brain Res. 107, 183–189. doi: 10.1016/S0169-328X(02)00498-2

Oishi, T. R., Brez J. N., Williams, N. M., Norton, N., Morello, Y., Ponsos, A. A., et al. (2006). Consistent evidence for Z′-s-cyclic nucleotide 5′-phosphodiesterase as a possible susceptibility gene for schizophrenia. Arch. Gen. Psychiatry 63, 18–24. doi: 10.1001/archpsyc.63.1.18

Pelek, S., and Poles, E. (2003). The local distribution of immunoreacted axons at nodes of Ranvier. Nat. Rev. Neurosci. 4, 906–909. doi: 10.1038/nrn1190

Phukuran, S., Sratan, J. E., Bryan, M. M., Hufsky, S. J., Huang, J. T., Griffin, J. L., et al. (2004). Mitochondrial dysfunction in schizophrenia: evidence for compromised brain metabolism and oxidative stress. Mol. Psychiatry 9, 684–693. doi: 10.1038/mp.001511

Qu, W., Guo, J., Xing, Q., Yang, J., Qin, X., Li, J., X., et al. (2005). A family-based association study of PLP1 and schizophrenia. Neurosci. Lett. 375, 207–210. doi: 10.1016/j.neulet.2004.11.053

Ren, Y., Wang, Y., and Xiao, L. (2013). Improving myelin/oligodendrocyte-related dysfunction: a new mechanism of antipsychotics in the treatment of schizophrenic J. Neural Transm. 120, 691–700. doi: 10.1007/s00702-012-1020-0

Ripke, S., O’Donnell, C., Cichon, S., Morain, A. J., Kalten, A. K., Alkenas, S. Brav, M. S., Semple, C., et al. (2015). Association analysis of the DISC1 gene with schizophrenia and psychosis in the postmortem brain and DISC1 immunoreactivity in the postmortem brain. Neurosci. Res. 77, 222–227. doi: 10.1016/j.neures.2015.08.010

Roussos, P., Giakoumaki, S. G., Adamaki, E., and Bitsios, P. (2011). The influence of transcription factor 4 as an important determinant of gating nodes of Ranvier. Neurosci. Res. 69, 17–25. doi: 10.1016/j.neures.2010.11.017

Roussos, P. (2012). Transcription factor 4 as an important determinant of gating nodes of Ranvier. Neurosci. Res. 69, 4746–4751. doi: 10.1016/j.neures.2010.09.019

Roussos, P., Bostedt, P., Davis, K. L., Norton, N., Morello, Y., and Harkous, Y. (2012). A system-level transcriptomic analysis of schizophrenia using postmortem brain tissue samples. Arch. Gen. Psychiatry 69, 1205–1213. doi: 10.1001/archgenpsychiatry.2012.768

Santos, P., Agazzi, I. De Francisuic, A., Lindmark, P., Djerovic, S., Kakhet, A., et al. (2008). Association between a disrupted-in-schizophrenia 1 (DISC1) single

"fncel-08-00005" — 2014/1/18 — 19:38 — page #6 — #6
methyl CpG binding protein and schizophrenia in a combined Scandinavian case-control sample. Schizophr Res. 106, 257–261. doi: 10.1016/j.schres.2008.08.024

Sequeira, P. A., Martin, M. V., and Vawter, M. P. (2012). The first decade and beyond of transcriptional profiling in schizophrenia. Neurosci. Biobehav. Rev. 36, 23–36. doi: 10.1016/j.neubiorev.2011.03.001

Silberghe, G., Darvan, A., Pikkar-Kranumurki, R., and Naren, B. (2006). The involvement of ErbB4 with schizophrenia: association and expression studies. Ann. J. Med. Genet. B Neuropsychiatr. Genet. 141B, 142–148. doi: 10.1002/ajmg.b.30275

Sklar, P., Ripke, S., Scott, L. J., Andreassen, O. A., Cichon, S., Craddock, N., et al. (2008). A large-scale genome-wide association analysis of bipolar disorder identifies a new susceptibility locus near ODZ4. Nat. Genet. 45, 977–983. doi: 10.1038/ng.104

Song, W., Li, W., Feng, J., Heston, L. L., Scaringe, W. A., and Sommer, S. S. (2008). Linking oligodendrocyte and myelin associated genes with schizophrenia. Proc. Natl. Acad. Sci. U. S. A. 105, 521, 93–97. doi: 10.1016/j.neulet.2012.05.040

Stefansson, H., Sigurdsson, E., Steinthorsdottir, V., Bjornsdottir, S., Sigmundsson, J., Marder, S., et al. (2007). A genome-wide search for schizophrenia identifies novel loci associated with schizophrenia and bipolar disorder. Nat. Genet. 39, 23–36.

Tan, W., Wang, Y., Gold, B., Chen, J., Dean, M., Harrison, P. J., et al. (2007). Neuregulin 1 and Susceptibility to Schizophrenia. Mol. Psychiatry 12, 143–146. doi: 10.1038/mp.2011.15

Tkachev, D., Mimmack, M. L., Ryan, M. M., Wayland, M., Freeman, T., Jones, P. B., et al. (2011). Linking oligodendrocyte dysfunction and myelin dysfunction in neurocircuitry abnormalities in schizophrenia. Prog. Neurobiol. 95, 13–24. doi: 10.1016/j.pneurobio.2010.09.004

Takahashi, N., Sakurai, T., Davis, K. L., and Buxbaum, J. D. (2011). Linking oligodendrocyte and myelin dysfunction to neurocircuitry abnormalities in schizophrenia. Proc. Natl. Acad. Sci. U. S. A. 108, 124, 192–199. doi: 10.1016/j.schres.2010.09.002

Tkatch, D., Moorhead, T. W., Whalley, H. C., Ffrench-Constant, M., Stefanis, N. C., Trikalinos, T. A., Avramopoulos, D., Smyrnis, N., Evdokimidis, I., Freeman, T., Jones, P. B., et al. (2008). A family-based association study of the methyl-associated glycoprotein and 2’,3’-cyclic nucleotide 3’-phosphohydrolase genes with schizophrenia. Psychol. Genet. 18, 143–146. doi: 10.1097/YPG.0b013e3282fa1874

Wan, C., Yang, Y., Feng, G., Gu, N., Liu, H., Zhu, S., et al. (2005). Polymorphisms of myelin-associated glycoprotein gene are associated with schizophrenia in the Chinese Han population. Neurosci. Lett. 388, 126–131. doi: 10.1016/j.neulet.2005.08.051

Wayland, M., Freeman, T., Jones, P. B., and Aragam, N. (2010). A genome-wide meta-analysis identifies novel loci associated with schizophrenia and bipolar disorder. Schizophr. Res. 124, 192–199. doi: 10.1016/j.schres.2010.08.082

Weickert, C. S., Tien, Y., Schiffrin, P. R., Mosry, B. J., and Fullerton, J. M. (2012). Schizophrenia-associated HaplE haplotype is associated with increased NRG1 type III expression and high nucleotide diversity. Brain. Res. Bull. 86, 458. doi: 10.1016/j.brainresbull.2012.23

Yuan, A., Yi, Z., Sun, J., Du, Y., Yu, T., Zhang, C., et al. (2012a). Effect of SOX10 gene polymorphism on early onset schizophrenia in Chinese Han population. Neurosci. Lett. 521, 93–97. doi: 10.1016/j.neulet.2012.05.040

Yuan, A., Yi, Z., Wang, Q., Sun, J., Li, Z., Du, Y., et al. (2012b). ANK3 as a risk gene for schizophrenia: new data in Han Chinese and meta-analysis. Am. J. Med. Genet. B Neuropsychiatr. Genet. 158B, 997–1005. doi: 10.1002/ajmg.b.32112

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.